Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology
Reference14 articles.
1. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update;Chin;J Clin Oncol,2017
2. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer;Hoskin;Radiother Oncol,2012
3. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: analysis of over 500 patients;Martell;Radiother Oncol,2019
4. Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?;Morton;Radiother Oncol,2011
5. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life;Roeloffzen;Int J Radiat Oncol Biol Phys,2010
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial;International Journal of Radiation Oncology*Biology*Physics;2023-12
2. Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis;Clinical and Translational Radiation Oncology;2023-01
3. Management of men with lower urinary tract symptoms referred for prostate radiotherapy;Journal of Clinical Urology;2022-10-17
4. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life;Radiotherapy and Oncology;2021-08
5. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial;Radiotherapy and Oncology;2021-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3